Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 3.8% - Should You Sell?

Key Points

• AUTL fell 3.8% to about $1.89 in Friday trading, with volume down 83% from its average.
• Analysts remain broadly optimistic, with a consensus rating of “Moderate Buy” and a $10.00 target price, despite mixed individual ratings.
• Autolus exceeded quarterly expectations, reporting a $0.15-per-share loss versus the estimated $0.21 loss and revenue of $45.69 million versus the $38.56 million forecast; however, the company remains unprofitable with a negative net margin.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) fell 3.8% during trading on Friday . The stock traded as low as $1.90 and last traded at $1.8850. Approximately 309,988 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 1,803,238 shares. The stock had previously closed at $1.96.

Analysts Set New Price Targets

Several research analysts have weighed in on AUTL shares. Weiss Ratings upgraded shares of Autolus Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 13th. HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Finally, Wall Street Zen upgraded Autolus Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $10.00.

Autolus Therapeutics Price Performance

The company has a market capitalization of $501.71 million, a PE ratio of -1.78 and a beta of 2.10. The company has a current ratio of 4.89, a quick ratio of 4.40 and a debt-to-equity ratio of 1.04. The company's 50 day moving average price is $1.92 and its 200-day moving average price is $1.68.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%.The business had revenue of $45.69 million for the quarter, compared to analyst estimates of $38.56 million. On average, sell-side analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.75 earnings per share for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC increased its holdings in Autolus Therapeutics by 115.6% in the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company's stock valued at $25,000 after buying an additional 8,309 shares during the last quarter. Independent Advisor Alliance acquired a new position in shares of Autolus Therapeutics in the 4th quarter worth approximately $28,000. Marex Group plc acquired a new position in shares of Autolus Therapeutics in the 2nd quarter worth approximately $28,000. Waverly Advisors LLC bought a new stake in shares of Autolus Therapeutics in the 1st quarter valued at approximately $37,000. Finally, SmartHarvest Portfolios LLC acquired a new stake in shares of Autolus Therapeutics during the 4th quarter valued at approximately $43,000. Institutional investors and hedge funds own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.